Clinical proteomics towards multiomics in cancer

Recent technological advancements in mass spectrometry (MS)-based proteomics technologies have accelerated its application to study greater and greater numbers of human tumor specimens. Over the last several years, the Clinical Proteomic Tumor Analysis Consortium, the International Cancer Proteogenome Consortium, and others have generated MS-based proteomic profiling data combined with corresponding multiomics data on thousands of human tumors to date. Proteomic data sets in the public domain can be re-examined by other researchers with different questions in mind from what the original studies explored. In this review, we examine the increasing role of proteomics in studying cancer, along with the potential for previous studies and their associated data sets to contribute to improving the diagnosis and treatment of cancer in the clinical setting. We also explore publicly available proteomics and multi-omics data from cancer cell line models to show how such data may aid in identifying therapeutic strategies for cancer subsets.

Automated summary

Recent technological advancements in mass spectrometry (MS)-based proteomics have allowed for greater study of human tumor specimens and the generation of large-scale proteomic profiling data combined with multiomics data. These datasets can be revisited by researchers for different purposes than the original studies. This review examines the increasing role of proteomics in cancer research and the potential of previous studies and associated data to improve cancer diagnosis and treatment. It also explores publicly available proteomics and multi-omics data on cancer cell line models and how this information can contribute to the identification of therapeutic strategies for specific cancer subsets.